Description: Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Home Page: www.medicenna.com
MDNA Technical Analysis
2 Bloor Street West
Toronto,
ON
M4W 3E2
Canada
Phone:
416 648 5555
Officers
| Name | Title |
|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, Pres & CEO |
| Ms. Rosemina Merchant B.Sc., M.E.Sc | Founder, Chief Devel. Officer & Director |
| Ms. Elizabeth Williams C.A., CPA, CA, CPA | CFO & Corp. Sec. |
| Dr. Martin Bexon M.D., MBBS | Acting Chief Medical Officer & Head of Clinical Devel. |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 204.0816 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3962 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 18 |